{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "ce3169a90d50f0f2430eda50dda8a529",
    "title": "Bime R4W TRx slightly up WoW; Poly run-rate still behind Barclays f/c",
    "source_uri": "2025-08-29/UCB SA Bime R4W TRx slightly up WoW Poly run-rate still behind Barclays fcUCB SA Bime R4W TRx slightly up WoW Poly run-r_2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T23:50:43.750395",
      "extracted_at": "2025-10-26T23:50:43.750402"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 12,
        "successful_pages": 12,
        "date": "2025-08-29",
        "publication": "2025-08-29",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 9,
          "removed_paragraphs": 37,
          "reduction_ratio": 0.5893987795780171
        },
        "input_relative_path": "2025-08-29"
      }
    }
  },
  "passages": [
    {
      "passage_id": "70627f5c72b9d0b8",
      "text": "Updated to include 22 Aug, Bimzelx rolling four- week average TRx increased \\(+0.8\\%\\) (WoW). Refreshing our IQVIA- implied 2H25 TRx we see poly/lin run- rate as \\(- 5\\% / + 8\\%\\) vs Barclays. Despite tariff/MFN overhangs, we see significant upside to shares driven by Bimzelx growth and reiterate Ow.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "4d696d76082fba55",
      "text": "Owing to enhanced reporting for independent and small chain pharmacies and an additional review and refinement to Rx validation parameters, IQVIA TRx/NRx data has been retroactively restated since launch through June 2025.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "26475c0895c86463",
      "text": "Updating our weekly US TRx/NRx data to 22 Aug, Bimzelx reported WoW TRx decreased \\(- 0.1\\%\\) (5,631 vs. 5,637 week ending 15 Aug) as NRx decreased \\(- 6.1\\%\\) (1,938 vs. 2,064). On a 4- week rolling basis (R4W), Bimzelx TRx increased \\(+0.8\\%\\) (5,590 vs. 5,547) as NRx decreased \\(- 2.5\\%\\) (1,938 vs. 2,110 last week). R4W TRx / working day increased \\(+0.8\\%\\) (1,118 vs. 1,109 last week), NRx / working day decreased \\(- 2.5\\%\\) (411.5 vs. 422 last week).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "35d66b3e35d98586",
      "text": "Based on our 2H25 US Bimzelx sales forecasts (€781m US, €1,090m group vs BBG consensus €915m, \\(+19\\%\\) ), our IQVIA analysis suggests that this translates to c150k TRx for 2H25, requiring an average weekly CAGR of \\(+0.6\\%\\) . Reporting a total of 43,090 so far in 2HTD, the polynomial line of best fit since HS launch in January 2025 suggests Bimzelx is on track to deliver c142k TRx, requiring an average 2H25 weekly CAGR of \\(+0.1\\%\\) . If we instead consider a linear line- of- best fit, this implies Bimzelx is on track to deliver c162k TRx, requiring a \\(+1.2\\%\\) weekly CAGR. Preferring a polynomial line of best fit, we conservatively conclude that the IQVIA TRx run- rate is c- \\(5\\%\\) vs our forecasts (vs a linear \\(+8\\%\\) ).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "04b68c6efa32ac38",
      "text": "UCB reported stellar 25 earnings and upgraded FY25 guidance on brisk Bimzelx performance, particularly driven by ramp- up in high potential HS indication (see: UCB SA 1H25 results: Expect outperformance on Bimzelx \\(+32\\%\\) beat & FY25 guidance raise; 31/07/25). Given the quality of the asset and growth story, we expect the company to strongly outperform over the long term, but ONLY once we have greater clarity on the design and impact of potential US tariff policies, as we believe UCB is one of the MOST exposed European pharma companies (see: EU Pharma: Field & Pitman's Tariff Toolkit and scenario analysis; AZN/ROG/GRF appear most protected, 10/04/25). However, supported by the commentary of CCO Emmanuel Caeymaex",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b993bedfe0768e83",
      "text": "This research report has been prepared in whole or in part by equity research analysts based outside the US who are not registered/qualified as research analysts with FINRA.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d413a7694053a384",
      "text": "Please see analyst certifications and important disclosures beginning on page 6. Completed: 29- Aug- 25, 11:08 GMT Released: 29- Aug- 25, 11:09 GMT Restricted - External",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "e5cf155576c1fca3",
      "text": "European Pharmaceuticals & Life Sciences",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "2e7c5f6748389988",
      "text": "Potential Upside/Downside",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "cbde3226a094efb4",
      "text": "Source: Bloomberg, Barclays Research",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7de8e635459cc1cc",
      "text": "European Pharmaceuticals & Life Sciences",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1db14433fe7e850c",
      "text": "Charles Pitman- King, CFA",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ae1e70d3e8c02d67",
      "text": "Anurag Surendra Sharma",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "11ea2f005bd92fd1",
      "text": "during our recent fireside chat (UCB SA: Feedback from CCO call; Is it time for round two? (29/04/25), Replay: Barclays: Conversations with the C-Suite 2025 - EU Healthcare - UCB (UCB) - CCO (30/04/25)) we are more confident that UCB holds levers to address tariff risks, but with likely significant price differentials between US and ex-US for key drugs, we now see a low- POS but high- risk MFN overhang.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "dc1d0e7868303f63",
      "text": "We reiterate our Overweight rating for UCB (€250 PT), as we believe the strong TRx growth of key growth drug Bimzelx is well placed to continue to support positive estimates momentum over FY25. We forecast peak Bimzelx sales of €7.5bn in 2032E vs. company guidance >€4bn, and reiterate that we see a positive risk- reward into the upcoming MLTX P3 VELA- 1/- 2 trials of SLK in HS (see UCB SA: Deep dive: HS market & pipeline landscape; Raise PT to €250, 11/08/25). This is based on the strong TRx data reported to date (see European Pharmaceuticals and Life Science: Prescription data for the month of June, 19/08/25).",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "8ddce0cca51132fe",
      "text": "With ongoing US tariff uncertainty, given UCB's top- line sales' high reliance on Bimzelx US growth and the drug's likely European manufacturing footprint, we do not expect to see UCB outperform until we get further insight into the likely implications for earnings. We would note that in a potential grey- sky tariff scenario, if we were to eliminate €25% of our total company NPV, our valuation would mechanically remain at €188 (c- 6% potential downside). Considering MFN and reflecting a c2/3 differential between US and ex- US pricing, if we reduced our assumed US Bimzelx sales by c2/3s, our valuation would mechanically also remain at €200/sh (implied 0%), illustrating the limited degree of downside that we now see in UCB shares in the face of macro uncertainty.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "fb150ad5012aa1ad",
      "text": "FIGURE 1. Bimzelx TRx and NRx from IQVIA - Weekly",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "4dd514b58b5b150c",
      "text": "Source: Barclays Research, RAPID Weekly Audit, November 2023 - Aug 2025 Copyright IQVIA. All rights reserved",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "40d5cb1e0163ad53",
      "text": "Owing to non- availability of the back- dated IQVIA weekly Rx data - for the peer therapies - to track weekly performance since launch, we switch to tracking relative performance on a monthly basis.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "a4e44808107cf5cb",
      "text": "FIGURE 2. Bimzelx TRx and NRx from Symphony Health - Weekly",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "3cfac9f1cb3685d4",
      "text": "Source: Barclays Research, Symphony Health",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "63de5c4b99f755f2",
      "text": "FIGURE 3. Bimzelx TRx and NRx from IQVIA - Monthly",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "a3cbaedc8b8931fa",
      "text": "Source: Barclays Research, Integrated Monthly, November 2023 - May 2025 Copyright IQVIA. All rights reserved",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "a2fff22fba672ffc",
      "text": "Barclays forecasts vs IQVIA TRx run-rate",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "e5b792de3bb01f7c",
      "text": "FIGURE 4. Barclays Sales and implied TRx vs IQVIA IMS run-rate and forecast TRx",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "b5f9d2d27702505d",
      "text": "BARC Bimzelx US,€m2H2320231H242H2420241H252H252025Barclays - PeriodSales99852022875457811,326TRx (Mthly IMS/forecast)1,0561,05619,31741,64360,96098,368149,965248,333GtN55.6%52.3%53.3%65.1%65.0%65.0%R4W CAGR7.8%2.1%4.9%3.5%0.6%2.1%IMS TRxTRx-Sum (HTD)90090017,99639,15257,14897,29243,090R4W CAGR-(HTD)29.4%29.4%2.1%7.0%4.7%3.6%1.2%TRx (Poly)-Sum (Period)97,292142,267239,559% Diff-15%-15%-7%-6%-6%-1%-5%-4%R4W CAGR-(Period)3.5%0.1%1.8%CAGR-Diff,bps0-46-23Sales-Implied5397411,280TRx (Lin)-Sum (Period)97,292161,923259,215% Diff-15%-15%-7%-6%-6%-1%8%4%R4W CAGR-(Period)3.5%1.2%2.4%CAGR-Diff,bps06633Sales-Implied5398431,382",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "91fb220db0a931ed",
      "text": "Source: Barclays Research, RAPID Weekly Audit, November 2023 - Aug 2025 Copyright IQVIA. All rights reserved",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "41eef90c0c0da58f",
      "text": "FIGURE 5. Barclays 2H25 sales forecast and implied TRx vs IQVIA IMS run-rate and forecast TRx",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "ed869d46e29977ad",
      "text": "Source: Barclays Research, RAPID Weekly Audit, November 2023 - Aug 2025 Copyright IQVIA. All rights reserved",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "34321e275eeb8384",
      "text": "On an absolute basis, we would note that Bimzelx TRx has started to surpass best- in- class immunology assets.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "c778f352a99e7ba9",
      "text": "FIGURE 6. Bimzelx TRx vs. peers reset to launch",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "8d7b6e7083f58124",
      "text": "Source: Barclays Research, Integrated Monthly, November 2023- March 2025 Copyright IQVIA. All rights reserved",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "11f15f2ad0d04778",
      "text": "FIGURE 7. Bimzelx NRx vs. peers",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "588b53c280fa11b1",
      "text": "Source: Barclays Research, Integrated Monthly, November 2023-March 2025 Copyright IQVIA. All rights reserved",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "d20dc885311a99e5",
      "text": "We, Emily Field, CFA, Sidhartha Modi, Charles Pitman- King, CFA, Shirley Chen, PhD and Yihan Li, PhD, hereby certify (1) that the views expressed in this research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "c67bf124bf922121",
      "text": "UCB SA (UCB.BR, 28- Aug- 2025, EUR 200.40), Overweight/Neutral, E/J/K/L/M",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "3673fafae017338c",
      "text": "Unless otherwise indicated, prices are sourced from Bloomberg and reflect the closing price in the relevant trading market, which may not be the last available closing price at the time of publication.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "36933477f719e47a",
      "text": "P: A partner, director or officer of Barclays Capital Canada Inc. has, during the preceding 12 months, provided services to the subject company for remuneration, other than normal course investment advisory or trade execution services.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "009186d02ab012a4",
      "text": "R: Barclays Capital Canada Inc. has received compensation for investment banking services from this issuer in the past 12 months.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "f6be62357591e531",
      "text": "S: This issuer is a Corporate Broker to Barclays PLC.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "4029cdf07590ac7f",
      "text": "U: The equity securities of this Canadian issuer include subordinate voting restricted shares.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "a0bd55eb26ecfe46",
      "text": "V: The equity securities of this Canadian issuer include non- voting restricted shares.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "3188be615968a9ab",
      "text": "The enclosed materials include information derived from market research information provided by IQVIA, Inc. and its affiliated companies (\"IQVIA\"). IQVIA market research information is proprietary to IQVIA and available on a confidential basis by subscription from IQVIA. IQVIA market research information reflects estimates of marketplace activity and should be treated accordingly. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IQVIA Inc. or any of its affiliated or subsidiary entities. Any analysis is independently arrived at by Barclays, on the basis of information from various sources.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "9290e413b83b853a",
      "text": "Overweight - The stock is expected to outperform the unweighted expected total return of the industry coverage universe over a 12- month investment horizon.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "fe07b0e614a1cceb",
      "text": "Equal Weight - The stock is expected to perform in line with the unweighted expected total return of the industry coverage universe over a 12- month investment horizon.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "b6f256ff5a2db015",
      "text": "Underweight - The stock is expected to underperform the unweighted expected total return of the industry coverage universe over a 12- month investment horizon.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "ce05da564459e84b",
      "text": "Positive - industry coverage universe fundamentals/valuations are improving.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "321873f9829d244d",
      "text": "Neutral - industry coverage universe fundamentals/valuations are steady, neither improving nor deteriorating.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "d60985e416a587f1",
      "text": "Negative - industry coverage universe fundamentals/valuations are deteriorating.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "33d08e3434328730",
      "text": "Below is the list of companies that constitute the \"industry coverage universe\":",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "65dccf2158d94ae8",
      "text": "European Pharmaceuticals & Life Sciences argenx (ARGX.BR)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "0e347c1aa2f10535",
      "text": "Bachem Holding AG (BANB.S)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "b821a034a494e30e",
      "text": "Bayer AG (BAYGN.DE) Galapagos (GLPG.AS) Galderma (GALD.S) Genmab A/S (GMAB.CO) Grifols SA (GRLS.MC) GSK plc (GSK.L) H Lundbeck A/S (HLUNB.CO) Hikma Pharmaceuticals PLC (HIK.L) Ipsen SA (IPN.PA) Lonza Group AG (LONN.S) Merck KGaA (MRCG.DE) Novartis (NOVN.S) Novo Nordisk (NOVOB.CO) Polypeptide Group AG (PPGN.S) Recordati (RECI.MI) Roche (ROG.S) Sandoz AG (SDZ.S) Sanofi (SASY.PA) Sartorius AG (SATG_p.DE) Sartorius Stedim Biotech (STDM.PA) Swedish Orphan Biovitrum (SOBIV.ST) UCB SA (UCB.BR) Zealand Pharma A/S (ZELA.CO)",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "79f630e58ea3ad04",
      "text": "In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts within Equity Research. Any such investment recommendations shall remain open until they are subsequently amended, rebalanced or closed in a future research report.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "23ee617d5cb7a571",
      "text": "Barclays may also re- distribute equity research reports produced by third- party research providers that contain recommendations that differ from and/or conflict with those published by Barclays' Equity Research Department.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "ce8c58125ce7db3a",
      "text": "Barclays Equity Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays Equity Research in the preceding 12 months please refer to https://live.barcap.com/go/research/Recommendations.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "70305eeb86e5afd3",
      "text": "Stock Rating: OVERWEIGHTIndustry View: NEUTRALClosing Price: EUR 200.40 (28-Aug-2025)",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "a0e2eb888611f535",
      "text": "Rating and Price Target Chart - EUR (as of 28-Aug-2025)Currency= EUR",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "792838c8c4f688b3",
      "text": "Source: IDC, Barclays Research",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "cf1eb46447239ecb",
      "text": "Link to Barclays Live for interactive charting",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "a8ff8854e77787b9",
      "text": "Publication DateClosing Price*RatingAdjusted Price Target10-Aug-2025184.50250.0024-Nov-2024174.15240.0028-Jul-2024152.05175.0023-Jun-2024139.10160.0017-Apr-2024119.35150.0005-Mar-2024107.90130.0020-Nov-202368.52117.0024-Jul-202382.02125.0005-Dec-202274.04Overweight120.00",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "102dbcc5705acd2d",
      "text": "On 29- Aug- 2022, prior to any intra- day change that may have been published, the rating for this security was Equal Weight, and the adjusted price target was 80.00.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "f0e11f741280e820",
      "text": "Source: Bloomberg, Barclays Research",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "279b7d1f8fcd140d",
      "text": "\\*This is the closing price referenced in the publication, which may not be the last available closing price at the time of publication.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "3ddf4ad67bcaf485",
      "text": "Historical stock prices and price targets may have been adjusted for stock splits and dividends.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "534d223e5c4bd61f",
      "text": "Valuation Methodology: We value UCB using both a top- down and a bottom- up NPV approach. At €250/sh, we value UCB at 1.2x FY25x PEG vs. the EU midcap pharma sector at 1.5x, and 2.2x EV/sales in 2032. Given UCB's significant operational leverage during the launch of Bimzelx, and its above- sector growth prospects to 2028E, we remain Overweight, preferring this quality growth pharma name within the context of our relative rating system.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "45557987c6f04b58",
      "text": "Risks which May Impede the Achievement of the Barclays Research Valuation and Price Target: Key up/downside risks include the outperformance of the Bimzelx launch in US and ex- US, reporting US TRx data since November 2023, potential Cimzia price pressure from the launch of biosimilars (c2028/29E), the outperformance of neurology products Rystiggo, Zylbrysq and Fintelpa. We also see upside potential from UCB's collection of P2a/3 pipeline assets, particularly for AD.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "149e7c6747c7578d",
      "text": "This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of Canadian Investment Regulatory Organization (www.ciro.ca), and a Member of the Canadian Investor Protection Fund (CIPF).",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "faa160b43b44a5c8",
      "text": "This communication is directed at persons who are a \"Wholesale Client\" as defined by the Australian Corporations Act 2001.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "7319453ad21ffc12",
      "text": "Middle East: Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 (\"Advisory Law\"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "320620ab33d0b25e",
      "text": "Russia: This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non- Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "4d177ad14d3bcdaf",
      "text": "Sustainable Investing Related Research: There is currently no globally accepted framework or definition (legal, regulatory or otherwise) of, nor market consensus as to what constitutes a 'sustainable', 'ESG', 'green', 'climate-friendly' or an equivalent company, investment, strategy or consideration or what precise attributes are required to be eligible to be categorised by such terms. This means there are different ways to evaluate a company or an investment and so different values may be placed on certain sustainability credentials as well as adverse ESG- related impacts of companies and ESG controversies. The evolving nature of sustainable investing considerations, models and methodologies means it can be challenging to definitively and universally classify a company or investment under a sustainable investing label and there may be areas where such companies and investments could improve or where adverse ESG- related impacts or ESG controversies exist. The evolving nature of sustainable finance related regulations and the development of jurisdiction- specific regulatory criteria also means that there is likely to be a degree of divergence as to the interpretation of such terms in the market. We expect industry guidance, market practice, and regulations in this field to continue to evolve.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "7bcc84ff412f1709",
      "text": "Any information, data, image, or other content including from a third party source contained, referred to herein or used for whatsoever purpose by Barclays or a third party (\"Information\"), in relation to any actual or potential 'ESG', 'sustainable' or equivalent objective, issue, factor or consideration is not intended to be relied upon for ESG or sustainability classification, regulatory regime or industry initiative purposes (\"ESG Regimes\"), unless otherwise stated. Nothing in these materials, including any images included therein, is intended to convey, suggest or indicate that Barclays considers or represents any product, service, person or body mentioned in these materials as meeting or qualifying for any ESG or sustainability classification, label or similar standards that may exist under ESG Regimes. Barclays has not conducted any assessment of compliance with ESG Regimes. Parties are reminded to make their own assessments for these purposes.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "863603d13e578be1",
      "text": "IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax- related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.",
      "page": 11,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "8ecf5f701f73bde6",
      "name": "Adjusted Price",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d1cf412485ca8530",
      "name": "Advisory Law",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "370d208bf6a8a468",
      "name": "Anurag Surendra",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "facedae141187a9f",
      "name": "Australian Corporations",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "be35f9655655259f",
      "name": "BARC Bimzelx",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2911ec4593e8e353",
      "name": "Bachem Holding",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "46a2e39eafb9f3ae",
      "name": "Barclays Capital",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "64387d09d2494c79",
      "name": "Barclays Capital Canada Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4d2d57430a6b5e51",
      "name": "Barclays Equity",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d1d3bfaf58595d0a",
      "name": "Barclays Israeli",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "05ab2ec667d770bf",
      "name": "Barclays Live",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "520bb613ae942fa6",
      "name": "Barclays PLC",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ccf133d649c357ba",
      "name": "Barclays Research",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "41a23983548dce29",
      "name": "Barclays Sales",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a99050f978a6bc4a",
      "name": "Bayer AG",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8a3c440ee1be96d9",
      "name": "Bimzelx NRx",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2099d5c4ea1edabd",
      "name": "Bimzelx TRx",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a67ebef55d0e7182",
      "name": "Bimzelx US",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "70406d536957c267",
      "name": "CCO Emmanuel",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d8584aacf8854c8c",
      "name": "CFA\n\nEmily",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "area",
        "title": "Bimzelx TRx and NRx from Symphony Health - Weekly",
        "page": 3,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "03-Nov-23",
              "17-Nov-23",
              "01-Dec-23",
              "15-Dec-23",
              "29-Dec-23",
              "12-Jan-24",
              "26-Jan-24",
              "09-Feb-24",
              "23-Feb-24",
              "08-Mar-24",
              "22-Mar-24",
              "05-Apr-24",
              "19-Apr-24",
              "03-May-24",
              "17-May-24",
              "31-May-24",
              "14-Jun-24",
              "28-Jun-24",
              "12-Jul-24",
              "26-Jul-24",
              "09-Aug-24",
              "23-Aug-24",
              "06-Sep-24",
              "20-Sep-24",
              "04-Oct-24",
              "18-Oct-24",
              "01-Nov-24",
              "15-Nov-24",
              "29-Nov-24",
              "13-Dec-24",
              "27-Dec-24",
              "10-Jan-25",
              "24-Jan-25",
              "07-Feb-25",
              "21-Feb-25",
              "07-Mar-25",
              "21-Mar-25",
              "04-Apr-25",
              "18-Apr-25",
              "02-May-25",
              "16-May-25",
              "30-May-25",
              "13-Jun-25",
              "27-Jun-25",
              "11-Jul-25",
              "25-Jul-25",
              "08-Aug-25",
              "22-Aug-25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 8000
            }
          }
        },
        "series": [
          {
            "name": "TRx",
            "unit": null,
            "values": [
              100,
              120,
              150,
              180,
              200,
              220,
              250,
              280,
              300,
              320,
              350,
              380,
              400,
              420,
              450,
              480,
              500,
              520,
              550,
              580,
              600,
              620,
              650,
              680,
              700,
              720,
              750,
              780,
              800,
              820,
              850,
              880,
              900,
              920,
              950,
              980,
              1000,
              1020,
              1050,
              1080,
              1100,
              1120,
              1150,
              1180,
              1200,
              1220,
              1250,
              1280
            ]
          },
          {
            "name": "NRx",
            "unit": null,
            "values": [
              150,
              180,
              220,
              260,
              300,
              340,
              380,
              420,
              460,
              500,
              540,
              580,
              620,
              660,
              700,
              740,
              780,
              820,
              860,
              900,
              940,
              980,
              1020,
              1060,
              1100,
              1140,
              1180,
              1220,
              1260,
              1300,
              1340,
              1380,
              1420,
              1460,
              1500,
              1540,
              1580,
              1620,
              1660,
              1700,
              1740,
              1780,
              1820,
              1860,
              1900,
              1940,
              1980,
              2020
            ]
          }
        ],
        "figure_id": "c736f96ffa6db46a",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 5,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "M1",
              "M2",
              "M3",
              "M4",
              "M5",
              "M6",
              "M7",
              "M8",
              "M9",
              "M10",
              "M11",
              "M12",
              "M13",
              "M14",
              "M15",
              "M16",
              "M17",
              "M18",
              "M19",
              "M20",
              "M21",
              "M22",
              "M23",
              "M24"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 20000
            }
          }
        },
        "series": [
          {
            "name": "Bimzelx (Nov 23)",
            "unit": null,
            "values": [
              0,
              100,
              300,
              700,
              1200,
              2000,
              4000,
              4500,
              5500,
              6000,
              6500,
              7500,
              8500,
              10000,
              10000,
              11500,
              14000,
              18000,
              19000,
              17000,
              15000,
              13000,
              14000,
              13000
            ]
          },
          {
            "name": "Skyrizi (May 19)",
            "unit": null,
            "values": [
              0,
              0,
              100,
              300,
              600,
              1000,
              1500,
              2000,
              2500,
              3000,
              3500,
              4000,
              6000,
              6000,
              7500,
              7800,
              8000,
              8500,
              9000,
              10000,
              10000,
              9500,
              10500,
              12500
            ]
          },
          {
            "name": "Cosentyx (Feb 15)",
            "unit": null,
            "values": [
              0,
              0,
              100,
              200,
              500,
              1000,
              2000,
              3000,
              4000,
              5000,
              6000,
              7000,
              7500,
              8000,
              9000,
              10000,
              11000,
              13000,
              14000,
              12000,
              12500,
              18000,
              19000,
              15000
            ]
          },
          {
            "name": "Taltz (Apr 16)",
            "unit": null,
            "values": [
              0,
              0,
              0,
              100,
              300,
              800,
              1500,
              2500,
              3500,
              4500,
              5500,
              6500,
              7000,
              9000,
              8000,
              7000,
              8000,
              9500,
              10000,
              13000,
              10000,
              11000,
              13000,
              15000
            ]
          },
          {
            "name": "Tremfya (Jul 17)",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              100,
              300,
              800,
              1200,
              1500,
              2000,
              2500,
              3500,
              3000,
              4000,
              3500,
              3000,
              4000,
              5000,
              4000,
              6000,
              5000,
              6500,
              6000,
              5500
            ]
          }
        ],
        "figure_id": "c7bfddf9cf95fce6",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "combo",
        "title": null,
        "page": 9,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jan-2023",
              "Jul-2023",
              "Jan-2024",
              "Jul-2024",
              "Jan-2025",
              "Jul-2025"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 50,
              "max": 300
            }
          }
        },
        "series": [
          {
            "name": "Closing Price",
            "unit": null,
            "values": [
              {
                "x": "Jan-2023",
                "y": 70
              },
              {
                "x": "Jul-2023",
                "y": 85
              },
              {
                "x": "Jan-2024",
                "y": 70
              },
              {
                "x": "Jul-2024",
                "y": 160
              },
              {
                "x": "Jan-2025",
                "y": 190
              },
              {
                "x": "Jul-2025",
                "y": 200
              }
            ]
          },
          {
            "name": "Target Price",
            "unit": null,
            "values": [
              {
                "x": "Jan-2023",
                "y": 120
              },
              {
                "x": "Jul-2023",
                "y": 125
              },
              {
                "x": "Jan-2024",
                "y": 115
              },
              {
                "x": "Jul-2024",
                "y": 150
              },
              {
                "x": "Jul-2024",
                "y": 175
              },
              {
                "x": "Jan-2025",
                "y": 240
              },
              {
                "x": "Jul-2025",
                "y": 250
              }
            ]
          },
          {
            "name": "Rating Change",
            "unit": null,
            "values": [
              {
                "x": "Jan-2023",
                "y": 120
              }
            ]
          }
        ],
        "figure_id": "dc0fe0594cdd9e11",
        "provenance": {
          "page": 9
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 5,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "M1",
              "M2",
              "M3",
              "M4",
              "M5",
              "M6",
              "M7",
              "M8",
              "M9",
              "M10",
              "M11",
              "M12",
              "M13",
              "M14",
              "M15",
              "M16",
              "M17",
              "M18",
              "M19",
              "M20",
              "M21",
              "M22",
              "M23",
              "M24"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 10000
            }
          }
        },
        "series": [
          {
            "name": "Bimzelx (Nov 23)",
            "unit": null,
            "values": [
              200,
              400,
              600,
              900,
              1200,
              1800,
              2000,
              2200,
              2400,
              2600,
              2800,
              3000,
              2200,
              2800,
              4000,
              4200,
              4400,
              7500,
              7000,
              5000,
              5500,
              5000,
              5500,
              6000
            ]
          },
          {
            "name": "Skyrizi (May 19)",
            "unit": null,
            "values": [
              300,
              500,
              800,
              1100,
              1500,
              2000,
              2500,
              3000,
              3800,
              4200,
              4800,
              5000,
              4000,
              3800,
              4200,
              4400,
              4600,
              4800,
              5000,
              5500,
              5800,
              5200,
              6000,
              8000
            ]
          },
          {
            "name": "Cosentyx (Feb 15)",
            "unit": null,
            "values": [
              100,
              200,
              400,
              700,
              1000,
              2500,
              2800,
              2600,
              2800,
              3000,
              3200,
              2800,
              2500,
              3000,
              3500,
              3000,
              3000,
              6000,
              5000,
              4500,
              6500,
              5000,
              7200,
              5500
            ]
          },
          {
            "name": "Taltz (Apr 16)",
            "unit": null,
            "values": [
              100,
              300,
              500,
              800,
              1300,
              1800,
              2200,
              2000,
              3000,
              3800,
              4200,
              3800,
              3500,
              4000,
              5500,
              4500,
              4200,
              5000,
              4000,
              3800,
              5500,
              4200,
              4500,
              6200
            ]
          },
          {
            "name": "Tremfya (Jul 17)",
            "unit": null,
            "values": [
              50,
              100,
              200,
              500,
              800,
              1200,
              1000,
              1500,
              1800,
              2200,
              2500,
              2000,
              1800,
              2000,
              2500,
              1800,
              2000,
              2500,
              2000,
              3200,
              2800,
              2500,
              3500,
              2800
            ]
          }
        ],
        "figure_id": "797a66a291f1e4e0",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "area",
        "title": null,
        "page": 3,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Nov 2023",
              "Dec 2023",
              "Jan 2024",
              "Feb 2024",
              "Mar 2024",
              "Apr 2024",
              "May 2024",
              "Jun 2024",
              "Jul 2024",
              "Aug 2024",
              "Sep 2024",
              "Oct 2024",
              "Nov-24",
              "Dec-24",
              "Jan-25",
              "Feb-25",
              "Mar-25",
              "Apr-25",
              "May-25",
              "Jun-25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 25000
            }
          }
        },
        "series": [
          {
            "name": "NRx",
            "unit": null,
            "values": [
              100,
              200,
              400,
              600,
              1000,
              1500,
              2000,
              2500,
              2800,
              3000,
              3200,
              3500,
              4000,
              4500,
              5000,
              5800,
              6500,
              7500,
              8500,
              9500
            ]
          },
          {
            "name": "TRx",
            "unit": null,
            "values": [
              200,
              400,
              800,
              1200,
              2000,
              3000,
              4000,
              5000,
              5600,
              6000,
              6400,
              7000,
              8000,
              9000,
              10000,
              11600,
              13000,
              15000,
              17000,
              19000
            ]
          }
        ],
        "figure_id": "bc6e719556af067d",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 4,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "03-Jan-25",
              "03-Feb-25",
              "03-Mar-25",
              "03-Apr-25",
              "03-May-25",
              "03-Jun-25",
              "03-Jul-25",
              "03-Aug-25",
              "03-Sep-25",
              "03-Oct-25",
              "03-Nov-25",
              "03-Dec-25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 8000
            }
          }
        },
        "series": [
          {
            "name": "R4W (Poly)",
            "unit": null,
            "values": [
              1950,
              1850,
              2100,
              2500,
              3000,
              3500,
              3800,
              4200,
              4500,
              4800,
              5000,
              5200,
              5500,
              5600,
              5500,
              5400,
              5500,
              5800,
              5700,
              5900,
              6100,
              5800,
              5300
            ]
          },
          {
            "name": "R4W (Lin)",
            "unit": null,
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              5700,
              5900,
              6200,
              6500,
              6700,
              6600,
              6800,
              7000,
              7200,
              7300
            ]
          },
          {
            "name": "BARC TRx - R4W",
            "unit": null,
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              5500,
              5400,
              5600,
              5800,
              5700,
              5900,
              6100,
              5800,
              5300
            ]
          }
        ],
        "figure_id": "91abe18ea166e0cb",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "other",
        "title": "加微信：IBReport 领取",
        "page": 4,
        "axes": null,
        "series": [],
        "figure_id": "69d4043d9c9008ba",
        "provenance": {
          "page": 4
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "3e672f8618895a7b",
        "value": 781.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "day decreased \\(- 2.5\\%\\) (411.5 vs. 422 last week). Based on our 2H25 US Bimzelx sales forecasts (€781m US, €1,090m group vs BBG consensus €915m, \\(+19\\%\\) ), our IQVIA analysis suggests that this tr",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "d114eb7a76db2dd6",
        "value": 1090.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "sed \\(- 2.5\\%\\) (411.5 vs. 422 last week). Based on our 2H25 US Bimzelx sales forecasts (€781m US, €1,090m group vs BBG consensus €915m, \\(+19\\%\\) ), our IQVIA analysis suggests that this translates t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "73191ec80bcf5452",
        "value": 915.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "last week). Based on our 2H25 US Bimzelx sales forecasts (€781m US, €1,090m group vs BBG consensus €915m, \\(+19\\%\\) ), our IQVIA analysis suggests that this translates to c150k TRx for 2H25, requiring",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "fbe0075a74ff7251",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "for earnings. We would note that in a potential grey- sky tariff scenario, if we were to eliminate €25% of our total company NPV, our valuation would mechanically remain at €188 (c- 6% potential downs",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "38d7a2685391d205",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ere to eliminate €25% of our total company NPV, our valuation would mechanically remain at €188 (c- 6% potential downside). Considering MFN and reflecting a c2/3 differential between US and ex- US pri",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "149378a47195fed1",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "assumed US Bimzelx sales by c2/3s, our valuation would mechanically also remain at €200/sh (implied 0%), illustrating the limited degree of downside that we now see in UCB shares in the face of macro ",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "f15da343ea227308",
        "value": 250.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "gs, we now see a low- POS but high- risk MFN overhang. We reiterate our Overweight rating for UCB (€250 PT), as we believe the strong TRx growth of key growth drug Bimzelx is well placed to continue t",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "c33390ae390bb486",
        "value": 7.5,
        "unit": "€",
        "metric_type": "currency",
        "context": "ced to continue to support positive estimates momentum over FY25. We forecast peak Bimzelx sales of €7.5bn in 2032E vs. company guidance >€4bn, and reiterate that we see a positive risk- reward into t",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "3de2dfea85e9d815",
        "value": 4.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "timates momentum over FY25. We forecast peak Bimzelx sales of €7.5bn in 2032E vs. company guidance >€4bn, and reiterate that we see a positive risk- reward into the upcoming MLTX P3 VELA- 1/- 2 trials",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "887e32de905214e7",
        "value": 250.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "VELA- 1/- 2 trials of SLK in HS (see UCB SA: Deep dive: HS market & pipeline landscape; Raise PT to €250, 11/08/25). This is based on the strong TRx data reported to date (see European Pharmaceuticals",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "da3b747e3accf4c2",
        "value": 25.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "for earnings. We would note that in a potential grey- sky tariff scenario, if we were to eliminate €25% of our total company NPV, our valuation would mechanically remain at €188 (c- 6% potential downs",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "1f828dc783e96ba8",
        "value": 188.0,
        "unit": "€",
        "metric_type": "currency",
        "context": ", if we were to eliminate €25% of our total company NPV, our valuation would mechanically remain at €188 (c- 6% potential downside). Considering MFN and reflecting a c2/3 differential between US and e",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "5d852b711ef2fc1b",
        "value": 200.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "f we reduced our assumed US Bimzelx sales by c2/3s, our valuation would mechanically also remain at €200/sh (implied 0%), illustrating the limited degree of downside that we now see in UCB shares in t",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "c34fcbb317fdad30",
        "value": 0.556,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0,960</td><td>98,368</td><td>149,965</td><td>248,333</td></tr><tr><td>GtN</td><td></td><td></td><td>55.6%</td><td>52.3%</td><td>53.3%</td><td>65.1%</td><td>65.0%</td><td>65.0%</td></tr><tr><td>R4W CAG",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "3ab01f1fc3a5fd57",
        "value": 0.523,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "98,368</td><td>149,965</td><td>248,333</td></tr><tr><td>GtN</td><td></td><td></td><td>55.6%</td><td>52.3%</td><td>53.3%</td><td>65.1%</td><td>65.0%</td><td>65.0%</td></tr><tr><td>R4W CAGR</td><td></td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "2701b3d0224f7cc2",
        "value": 0.5329999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">149,965</td><td>248,333</td></tr><tr><td>GtN</td><td></td><td></td><td>55.6%</td><td>52.3%</td><td>53.3%</td><td>65.1%</td><td>65.0%</td><td>65.0%</td></tr><tr><td>R4W CAGR</td><td></td><td></td><td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "3e5b2bc1ce7d9640",
        "value": 0.6509999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>248,333</td></tr><tr><td>GtN</td><td></td><td></td><td>55.6%</td><td>52.3%</td><td>53.3%</td><td>65.1%</td><td>65.0%</td><td>65.0%</td></tr><tr><td>R4W CAGR</td><td></td><td></td><td>7.8%</td><td>2",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ac74cf956c47d474",
        "value": 0.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>GtN</td><td></td><td></td><td>55.6%</td><td>52.3%</td><td>53.3%</td><td>65.1%</td><td>65.0%</td><td>65.0%</td></tr><tr><td>R4W CAGR</td><td></td><td></td><td>7.8%</td><td>2.1%</td><td>4.",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "5aa80c431bc79d2a",
        "value": 0.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "GtN</td><td></td><td></td><td>55.6%</td><td>52.3%</td><td>53.3%</td><td>65.1%</td><td>65.0%</td><td>65.0%</td></tr><tr><td>R4W CAGR</td><td></td><td></td><td>7.8%</td><td>2.1%</td><td>4.9%</td><td>3.5",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "6ddb0e2dcf82c32a",
        "value": 0.078,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "53.3%</td><td>65.1%</td><td>65.0%</td><td>65.0%</td></tr><tr><td>R4W CAGR</td><td></td><td></td><td>7.8%</td><td>2.1%</td><td>4.9%</td><td>3.5%</td><td>0.6%</td><td>2.1%</td></tr><tr><td>IMS TRx</td><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "3fc02ca45c2dc36c",
        "value": 0.021,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">65.1%</td><td>65.0%</td><td>65.0%</td></tr><tr><td>R4W CAGR</td><td></td><td></td><td>7.8%</td><td>2.1%</td><td>4.9%</td><td>3.5%</td><td>0.6%</td><td>2.1%</td></tr><tr><td>IMS TRx</td><td></td><td><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "f0acb38ba938f082",
        "value": 0.049,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>65.0%</td><td>65.0%</td></tr><tr><td>R4W CAGR</td><td></td><td></td><td>7.8%</td><td>2.1%</td><td>4.9%</td><td>3.5%</td><td>0.6%</td><td>2.1%</td></tr><tr><td>IMS TRx</td><td></td><td></td><td></td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "22d01b0eeb25936f",
        "value": 0.035,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>65.0%</td></tr><tr><td>R4W CAGR</td><td></td><td></td><td>7.8%</td><td>2.1%</td><td>4.9%</td><td>3.5%</td><td>0.6%</td><td>2.1%</td></tr><tr><td>IMS TRx</td><td></td><td></td><td></td><td></td><td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "83e831993a79cad2",
        "value": 0.006,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>R4W CAGR</td><td></td><td></td><td>7.8%</td><td>2.1%</td><td>4.9%</td><td>3.5%</td><td>0.6%</td><td>2.1%</td></tr><tr><td>IMS TRx</td><td></td><td></td><td></td><td></td><td></td><td></td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "0c8adefc0cf128ac",
        "value": 0.021,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "R4W CAGR</td><td></td><td></td><td>7.8%</td><td>2.1%</td><td>4.9%</td><td>3.5%</td><td>0.6%</td><td>2.1%</td></tr><tr><td>IMS TRx</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "3f44372d76e9030d",
        "value": 0.294,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "9,152</td><td>57,148</td><td>97,292</td><td>43,090</td><td></td></tr><tr><td>R4W CAGR-(HTD)</td><td>29.4%</td><td>29.4%</td><td>2.1%</td><td>7.0%</td><td>4.7%</td><td>3.6%</td><td>1.2%</td><td></td></",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "6a8106d038a6459c",
        "value": 0.294,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "57,148</td><td>97,292</td><td>43,090</td><td></td></tr><tr><td>R4W CAGR-(HTD)</td><td>29.4%</td><td>29.4%</td><td>2.1%</td><td>7.0%</td><td>4.7%</td><td>3.6%</td><td>1.2%</td><td></td></tr><tr><td>TRx",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "be9dfcc18ef62ec8",
        "value": 0.021,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">97,292</td><td>43,090</td><td></td></tr><tr><td>R4W CAGR-(HTD)</td><td>29.4%</td><td>29.4%</td><td>2.1%</td><td>7.0%</td><td>4.7%</td><td>3.6%</td><td>1.2%</td><td></td></tr><tr><td>TRx (Poly)-Sum (P",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "f4b29f87e41a6cef",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>43,090</td><td></td></tr><tr><td>R4W CAGR-(HTD)</td><td>29.4%</td><td>29.4%</td><td>2.1%</td><td>7.0%</td><td>4.7%</td><td>3.6%</td><td>1.2%</td><td></td></tr><tr><td>TRx (Poly)-Sum (Period)</td><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "41f78e800806e89f",
        "value": 0.047,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td></td></tr><tr><td>R4W CAGR-(HTD)</td><td>29.4%</td><td>29.4%</td><td>2.1%</td><td>7.0%</td><td>4.7%</td><td>3.6%</td><td>1.2%</td><td></td></tr><tr><td>TRx (Poly)-Sum (Period)</td><td></td><td></",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "e4c1300451ca1d8b",
        "value": 0.036000000000000004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>R4W CAGR-(HTD)</td><td>29.4%</td><td>29.4%</td><td>2.1%</td><td>7.0%</td><td>4.7%</td><td>3.6%</td><td>1.2%</td><td></td></tr><tr><td>TRx (Poly)-Sum (Period)</td><td></td><td></td><td></td><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "8f5db7ebbc0f9f29",
        "value": 0.012,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "CAGR-(HTD)</td><td>29.4%</td><td>29.4%</td><td>2.1%</td><td>7.0%</td><td>4.7%</td><td>3.6%</td><td>1.2%</td><td></td></tr><tr><td>TRx (Poly)-Sum (Period)</td><td></td><td></td><td></td><td></td><td></",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "3c2447feb296a530",
        "value": -0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td><td></td><td></td><td>97,292</td><td>142,267</td><td>239,559</td></tr><tr><td>% Diff</td><td>-15%</td><td>-15%</td><td>-7%</td><td>-6%</td><td>-6%</td><td>-1%</td><td>-5%</td><td>-4%</td></tr><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "85d25447cd48deec",
        "value": -0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td>97,292</td><td>142,267</td><td>239,559</td></tr><tr><td>% Diff</td><td>-15%</td><td>-15%</td><td>-7%</td><td>-6%</td><td>-6%</td><td>-1%</td><td>-5%</td><td>-4%</td></tr><tr><td>R4W CA",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "efd5f8a9ea6310fa",
        "value": -0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>97,292</td><td>142,267</td><td>239,559</td></tr><tr><td>% Diff</td><td>-15%</td><td>-15%</td><td>-7%</td><td>-6%</td><td>-6%</td><td>-1%</td><td>-5%</td><td>-4%</td></tr><tr><td>R4W CAGR-(Period)</",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "208e16c0b2d6196f",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>142,267</td><td>239,559</td></tr><tr><td>% Diff</td><td>-15%</td><td>-15%</td><td>-7%</td><td>-6%</td><td>-6%</td><td>-1%</td><td>-5%</td><td>-4%</td></tr><tr><td>R4W CAGR-(Period)</td><td></td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ec4c42cf7fd9b55a",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7</td><td>239,559</td></tr><tr><td>% Diff</td><td>-15%</td><td>-15%</td><td>-7%</td><td>-6%</td><td>-6%</td><td>-1%</td><td>-5%</td><td>-4%</td></tr><tr><td>R4W CAGR-(Period)</td><td></td><td></td><td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "e3819756455524b2",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "9,559</td></tr><tr><td>% Diff</td><td>-15%</td><td>-15%</td><td>-7%</td><td>-6%</td><td>-6%</td><td>-1%</td><td>-5%</td><td>-4%</td></tr><tr><td>R4W CAGR-(Period)</td><td></td><td></td><td></td><td></",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "4ea9786aa92d8f7d",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>% Diff</td><td>-15%</td><td>-15%</td><td>-7%</td><td>-6%</td><td>-6%</td><td>-1%</td><td>-5%</td><td>-4%</td></tr><tr><td>R4W CAGR-(Period)</td><td></td><td></td><td></td><td></td><td></td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "27b21129b4a4ba9c",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Diff</td><td>-15%</td><td>-15%</td><td>-7%</td><td>-6%</td><td>-6%</td><td>-1%</td><td>-5%</td><td>-4%</td></tr><tr><td>R4W CAGR-(Period)</td><td></td><td></td><td></td><td></td><td></td><td>3.5%</td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "d9cc93c71cf163bb",
        "value": 0.035,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>-4%</td></tr><tr><td>R4W CAGR-(Period)</td><td></td><td></td><td></td><td></td><td></td><td>3.5%</td><td>0.1%</td><td>1.8%</td></tr><tr><td>CAGR-Diff,bps</td><td></td><td></td><td></td><td></t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b9fc95813789ec33",
        "value": 0.001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>R4W CAGR-(Period)</td><td></td><td></td><td></td><td></td><td></td><td>3.5%</td><td>0.1%</td><td>1.8%</td></tr><tr><td>CAGR-Diff,bps</td><td></td><td></td><td></td><td></td><td></td><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "cd5564b8e9475a85",
        "value": 0.018000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>R4W CAGR-(Period)</td><td></td><td></td><td></td><td></td><td></td><td>3.5%</td><td>0.1%</td><td>1.8%</td></tr><tr><td>CAGR-Diff,bps</td><td></td><td></td><td></td><td></td><td></td><td>0</td><td>-",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "3c2447feb296a530",
        "value": -0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td><td></td><td></td><td>97,292</td><td>161,923</td><td>259,215</td></tr><tr><td>% Diff</td><td>-15%</td><td>-15%</td><td>-7%</td><td>-6%</td><td>-6%</td><td>-1%</td><td>8%</td><td>4%</td></tr><tr",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "85d25447cd48deec",
        "value": -0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td>97,292</td><td>161,923</td><td>259,215</td></tr><tr><td>% Diff</td><td>-15%</td><td>-15%</td><td>-7%</td><td>-6%</td><td>-6%</td><td>-1%</td><td>8%</td><td>4%</td></tr><tr><td>R4W CAGR",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "1d8a51070d8c280c",
        "value": -0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>97,292</td><td>161,923</td><td>259,215</td></tr><tr><td>% Diff</td><td>-15%</td><td>-15%</td><td>-7%</td><td>-6%</td><td>-6%</td><td>-1%</td><td>8%</td><td>4%</td></tr><tr><td>R4W CAGR-(Period)</td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "45ceb88671bdd6d0",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>161,923</td><td>259,215</td></tr><tr><td>% Diff</td><td>-15%</td><td>-15%</td><td>-7%</td><td>-6%</td><td>-6%</td><td>-1%</td><td>8%</td><td>4%</td></tr><tr><td>R4W CAGR-(Period)</td><td></td><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "e1bfaca8bfb0d9cc",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3</td><td>259,215</td></tr><tr><td>% Diff</td><td>-15%</td><td>-15%</td><td>-7%</td><td>-6%</td><td>-6%</td><td>-1%</td><td>8%</td><td>4%</td></tr><tr><td>R4W CAGR-(Period)</td><td></td><td></td><td><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "843478c02d863760",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "9,215</td></tr><tr><td>% Diff</td><td>-15%</td><td>-15%</td><td>-7%</td><td>-6%</td><td>-6%</td><td>-1%</td><td>8%</td><td>4%</td></tr><tr><td>R4W CAGR-(Period)</td><td></td><td></td><td></td><td></td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a134dc57f7507c5b",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>% Diff</td><td>-15%</td><td>-15%</td><td>-7%</td><td>-6%</td><td>-6%</td><td>-1%</td><td>8%</td><td>4%</td></tr><tr><td>R4W CAGR-(Period)</td><td></td><td></td><td></td><td></td><td></td><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "49e9ed516b518c9e",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "% Diff</td><td>-15%</td><td>-15%</td><td>-7%</td><td>-6%</td><td>-6%</td><td>-1%</td><td>8%</td><td>4%</td></tr><tr><td>R4W CAGR-(Period)</td><td></td><td></td><td></td><td></td><td></td><td>3.5%</td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "8998ee886847b2c5",
        "value": 0.035,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>4%</td></tr><tr><td>R4W CAGR-(Period)</td><td></td><td></td><td></td><td></td><td></td><td>3.5%</td><td>1.2%</td><td>2.4%</td></tr><tr><td>CAGR-Diff,bps</td><td></td><td></td><td></td><td></t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "fd05a3abfd77b6d3",
        "value": 0.012,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>R4W CAGR-(Period)</td><td></td><td></td><td></td><td></td><td></td><td>3.5%</td><td>1.2%</td><td>2.4%</td></tr><tr><td>CAGR-Diff,bps</td><td></td><td></td><td></td><td></td><td></td><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9dbfa2611c7f1411",
        "value": 0.024,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>R4W CAGR-(Period)</td><td></td><td></td><td></td><td></td><td></td><td>3.5%</td><td>1.2%</td><td>2.4%</td></tr><tr><td>CAGR-Diff,bps</td><td></td><td></td><td></td><td></td><td></td><td>0</td><td>6",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "69701fc263eafbb7",
        "value": 250.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "Valuation Methodology: We value UCB using both a top- down and a bottom- up NPV approach. At €250/sh, we value UCB at 1.2x FY25x PEG vs. the EU midcap pharma sector at 1.5x, and 2.2x EV/sales in 20",
        "provenance": {
          "page": 9
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 7,
      "tables_count": 0,
      "numerical_data_count": 55,
      "passages_count": 74,
      "entities_count": 20
    }
  }
}